Advanced search

Comparing guidelines for the treatment of inflammatory bowel disease.

Joseph B Kirsner, Stephen B Hanauer

Journal: Digestive diseases (Basel, Switzerland) 2014;31(3-4):360-2

PMID: 24246988

Full Text on S. Karger AG, Basel, Switzerland View on PubMed

Abstract

As we enter into the era of 'personalized medicine', many of the recommendations of 'evidence-based medicine' require scrutiny and adaptation to optimize individual outcomes. Several examples of these discrepancies are exemplified by the topics of aminosalicylate use in Crohn's disease, early use of biologic agents that target TNF and the role of calcineurin inhibitors versus anti-TNF agents in steroid-refractory ulcerative colitis.

Address: Section of Gastroenterology, Hepatology and Nutrition, University of Chicago Medicine, Chicago, Ill., USA.
DOI: 10.1159/000354695

Link outs

Free resources

Other Literature Sources:

Research Materials:

Subscription / membership required

Full Text Sources:

MeSH Terms: Aminosalicylic Acid, Calcineurin, Calcineurin Inhibitors, Enzyme Inhibitors, Humans, Inflammatory Bowel Diseases, Practice Guidelines as Topic, Tumor Necrosis Factor-alpha
Bant logo

© Copyright 2026, Nutrition Evidence

NED wishes to thank the following organisations for their support:

Sponsor Sponsor Sponsor Sponsor Sponsor Sponsor Sponsor

We use cookies to improve your experience and analyze site traffic with Google Analytics. By continuing to use our site, you agree to our use of cookies. Learn more.